Clinical Trial Update: Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating lenvatinib plus letrozole versus fulvestrant in metastatic ER+/HER2- breast cancer after progression on an aromatase inhibitor and CDK4…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer

Drugs mentioned

• FEMARA (letrozole)
• Faslodex (fulvestrant)
• LENVIMA (lenvatinib)

Snippet

Sponsor: National University Hospital, Singapore | Conditions: Breast Cancer | Phase 2 | Status: RECRUITING